GSK Strikes $3.3B Oligonucleotide Pact with Wave Life Sciences

GSK Strikes $3.3B Oligonucleotide Pact with Wave Life Sciences

Source: 
BioSpace
snippet: 

GSK has bolstered its position in the oligonucleotide therapeutics space through a four-year collaboration with Wave Life Sciences valued at up to $3.3 billion.

In the partnership announced Tuesday, GSK will harness Wave’s PRISM technology, an oligonucleotide platform that combines novel chemistry with multiple therapeutic modalities, including editing, splicing and silencing.